Teva & Xenon Receive FDA 'Orphan Drug' status for EM treatment candidate

Teva and Xenon announced that Xenon's erythromelalgia drug in Phase 2 trials has received FDA "Orphan Drug" status.

This means that the companies are eligible to receive various tax deductions as well as some exclusive rights to develop the drug for 7 years.